A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer is spending more than $11 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own. The New York drugmaker said Tuesday, May 10, 2022, it will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has another nasal spray under development. (AP Photo/Mark Lennihan, File)
Featured Photo Galleries
Trump Transition: Here are the people Trump has picked for key positions so far
President-elect Donald Trump has announced a flurry of picks for his incoming administration. Get full coverage of the Trump transition from The Washingon Times.
Trump dances onstage, takes post-election nation by storm
President-elect Trump dances onstage
